World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 March 2021
Main ID:  NCT03933943
Date of registration: 30/04/2019
Prospective Registration: Yes
Primary sponsor: Eli Lilly and Company
Public title: A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
Scientific title: A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
Date of first enrolment: May 21, 2019
Target sample size: 28
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03933943
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).  
Phase:  Phase 1
Countries of recruitment
United States
Contacts
Name:     Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address: 
Telephone:
Email:
Affiliation:  Eli Lilly and Company
Key inclusion & exclusion criteria

Inclusion Criteria:

- Participants must have received a diagnosis of SLE at least 24 weeks before screening
(at least 4 of 11 criteria in 1997 revised American College of Rheumatology [ACR]
classification)

- If a participant is taking oral prednisone (or prednisone equivalent) for SLE, the
dose must be =20 milligrams per day (mg/day) for at least 8 weeks prior to screening,
and must have been stable for at least the last 2 weeks

- If a participant is taking any of the following medications for SLE, the medication
must have been used for at least 12 weeks and stable for at least the last 8 weeks:

- Azathioprine =200 mg/day

- Antimalarial (e.g., chloroquine, hydroxychloroquine, quinacrine)

- Mycophenolate mofetil =2 g/day or mycophenolic acid =1.44 grams per day (g/day)

- Oral, SC, or intramuscular methotrexate =15 milligrams per week (mg/week)

Exclusion Criteria:

- Participants must not have a history of, or current, inflammatory joint or skin
disease other than SLE

- Participants must not have a current active bacterial, viral, or fungal infection

- Participants must not have evidence of significant liver or kidney dysfunction

- Participants must not have received cytotoxic medications (e.g., cyclophosphamide)
within the last 3 months.

- Participants must not have received any intra-articular, intramuscular, or intravenous
glucocorticoids within the last 3 months

- Participants must not have received blood products (e.g., blood transfusion,
platelets, etc.) within the last 12 months



Age minimum: 18 Years
Age maximum: 70 Years
Gender: All
Health Condition(s) or Problem(s) studied
Lupus Erythematosus, Systemic
Intervention(s)
Drug: LY3361237
Drug: Placebo
Primary Outcome(s)
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug [Time Frame: Baseline through Day 155]
Secondary Outcome(s)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3361237 [Time Frame: Day 1 predose through Day 155]
PK: Area Under the Concentration Versus Time Curve (AUC) Over the Dosing Interval of LY3361237 [Time Frame: Day 1 predose through Day 155]
Secondary ID(s)
I9S-MC-BTAB
17180
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history